Recombinant Proteins iso9001 ISO13485
搜索
 > 【B7-2】重组蛋白信息

B7-2信息

英文名称:Cluster of differentiation 86
中文名称:分化群86
靶点别称:FUN-1,CTLA-4 counter-receptor B7.2,CD28LG2,Activation B7-2 antigen,CD86,CD86 Molecule,CD86 Antigen (CD28 Antigen Ligand 2, B7-2 Antigen),BU63,B70,B-Lymphocyte Activation Antigen B7-2,T-Lymphocyte Activation Antigen CD86,B-Lymphocyte Antigen B7-2,CD86 Anti
上市药物数量:2
临床药物数量:1
最高研发阶段:批准上市

B7-2产品列表

 
评论(1)
CD6-H5257|Human B7-2 / CD86 Protein, Fc Tag
  1. 173XXXXXXX2
  2. 0人赞
  3. SEC纯度很高,能达到90%以上,功能验证活性也很好,体外测试能与PD-L1结合。如果用于测亲和力的话,提高pdl1浓度信号会高一点
  4. 2019-09-26
 

B7-2 分子别名

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

B7-2 分子背景

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

B7-2 参考文献

B7-2上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg 批准上市 百时美施贵宝 Nulojix EU 肾脏移植排斥 Bristol-Myers Squibb Pharma Eeig 2011-06-15 肾脏移植排斥, 器官移植排斥 详情
Abatacept 阿巴西普 BMS-188667; BMS-188667SC; ONO-4164SC; ONO-4164 批准上市 百时美施贵宝 Orencia Mainland China 类风湿关节炎 Bristol-Myers Squibb Company 2005-12-23 多发性硬化, 克罗恩病, 肌病, 肾病综合征, 溃疡性结肠炎, 银屑病关节炎, 系统性红斑狼疮, 银屑病, 局灶性节段性肾小球硬化症, 多发性肌炎, 狼疮肾炎, 幼年型类风湿性关节炎, 微小病变性肾病, Sjtoegren综合征, 类风湿关节炎, 新型冠状病毒肺炎, 皮肌炎, 巨细胞性动脉炎 详情

B7-2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs 临床一期 湖南昭泰涌仁医疗创新有限公司 非小细胞肺癌

消息提示

请输入您的联系方式,再点击提交!

确定